



AUMAPHARMA

AUMAPHARMA, 215 Decatur Street, Doylestown PA 18901

April 2015

Dear colleague:

The courses of 2014 and 2015 have been amazing for Aumapharma, and we are looking forward to continue good consulting service, helping to bring pulmonary products to patients:

Specifically, Aumapharma has contributed to:

- A substantial program for Severe Asthma, including a milestone publication, and a major corporate transaction

<http://www.vectura.com/media/press-releases/2014/13-mar-2014.aspx>

Eur Respir J. 2014 Dec 10. pii: ERJ-01520-2014: **Nebulised budesonide using a novel device in patients with oral steroid-dependent asthma.** Vogelmeier C¹, Kardos P², Hofmann T³, Canisius S⁴, Scheuch G⁴, Muellinger B⁴, Nocker K⁴, Menz G⁵, Rabe KF⁶.

Several programs and activities in Cystic Fibrosis (various sponsors):

- Provide development plans
- Ensure enrollment of late Phase CF studies, in a competitive environment
- Support programs at FDA and EMA
- Ensure appropriate enrollment of studies in a competitive environment
- Full assessment of CF assets for Venture Capitalists, Companies

Other indications:

- Development programs in COPD, PAH, IPF
- Assembling and working on worldwide KOL boards

We are available as individuals, or as a virtual team, depending on your needs. Please reach out, and we will accommodate your needs.

Regards,

Thomas Hofmann MD PhD
CEO at Aumapharma